<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28941314</article-id><article-id pub-id-type="pmc">5836914</article-id><article-id pub-id-type="doi">10.1111/dom.13120</article-id><article-id pub-id-type="publisher-id">DOM13120</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Semaglutide improves postprandial glucose and lipid metabolism, and delays first&#x02010;hour gastric emptying in subjects with obesity</article-title><alt-title alt-title-type="left-running-head">Hjerpsted et al</alt-title></title-group><contrib-group><contrib id="dom13120-cr-0001" contrib-type="author" corresp="yes"><name><surname>Hjerpsted</surname><given-names>Julie B.</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6938-786X</contrib-id><address><email>jlhj@novonordisk.com</email></address><xref ref-type="aff" rid="dom13120-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom13120-cr-0002" contrib-type="author"><name><surname>Flint</surname><given-names>Anne</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom13120-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom13120-cr-0003" contrib-type="author"><name><surname>Brooks</surname><given-names>Ashley</given-names></name><degrees>MBChB</degrees><xref ref-type="aff" rid="dom13120-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom13120-cr-0004" contrib-type="author"><name><surname>Axelsen</surname><given-names>Mads B.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom13120-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom13120-cr-0005" contrib-type="author"><name><surname>Kvist</surname><given-names>Trine</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom13120-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom13120-cr-0006" contrib-type="author"><name><surname>Blundell</surname><given-names>John</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7085-9596</contrib-id><xref ref-type="aff" rid="dom13120-aff-0003">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="dom13120-aff-0001" content-type="private-address">
<label><sup>1</sup></label>
<institution>Novo Nordisk A/S</institution>
<named-content content-type="city">S&#x000f8;borg</named-content>
<country country="DK">Denmark</country>
</aff><aff id="dom13120-aff-0002" content-type="private-address">
<label><sup>2</sup></label>
<institution>Covance Clinical Research Unit Ltd</institution>
<named-content content-type="city">Leeds</named-content>
<country country="GB">UK</country>
</aff><aff id="dom13120-aff-0003" content-type="private-address">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Institute of Psychological Sciences, Faculty of Medicine and Health</named-content>
<institution>University of Leeds</institution>
<named-content content-type="city">Leeds</named-content>
<country country="GB">UK</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Julie B. Hjerpsted, Novo Nordisk A/S, Vandt&#x000e5;rnsvej 108&#x02010;110, 2860 S&#x000f8;borg, Denmark.<break/>
Email: <email>jlhj@novonordisk.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2018</year></pub-date><volume>20</volume><issue>3</issue><issue-id pub-id-type="doi">10.1111/dom.2018.20.issue-3</issue-id><fpage>610</fpage><lpage>619</lpage><history><date date-type="received"><day>26</day><month>4</month><year>2017</year></date><date date-type="rev-recd"><day>06</day><month>9</month><year>2017</year></date><date date-type="accepted"><day>08</day><month>9</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. <italic>Diabetes, Obesity and Metabolism</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-20-610.pdf"/><abstract><sec id="dom13120-sec-0001"><title>Aim</title><p>To investigate the effects of semaglutide on fasting and postprandial glucose and lipid responses, and on gastric emptying.</p></sec><sec id="dom13120-sec-0002"><title>Materials and methods</title><p>This was a randomized, double&#x02010;blind, placebo&#x02010;controlled, 2&#x02010;period, crossover trial. Subjects with obesity (N&#x02009;=&#x02009;30) received once&#x02010;weekly subcutaneous semaglutide, dose&#x02010;escalated to 1.0&#x02009;mg, or placebo. After each 12&#x02010;week treatment period, glucose and lipid metabolism were assessed before and after standardized meals. Gastric emptying (paracetamol absorption test) and peptide YY (PYY) response were also assessed.</p></sec><sec id="dom13120-sec-0003"><title>Results</title><p>Semaglutide treatment significantly lowered fasting concentrations of glucose and glucagon, and increased insulin vs placebo (estimated treatment ratio: 0.95 [95% confidence interval: 0.91, 0.98]; 0.86 [0.75, 0.98]; 1.45 [1.20, 1.75], respectively). Postprandial glucose metabolism significantly improved with semaglutide vs placebo (incremental area under the curve 0 to 5&#x02009;hours [iAUC<sub>0&#x02010;5h</sub>]; estimated treatment difference: glucose &#x02212;1.34&#x02009;mmol&#x02009;h/L [&#x02212;2.42, &#x02212;0.27]; insulin &#x02212;921&#x02009;pmol h/L [&#x02212;1461, &#x02212;381]; C&#x02010;peptide &#x02212;1.42&#x02009;nmol&#x02009;h/L [&#x02212;2.33, &#x02212;0.51]). Fasting and postprandial lipid metabolism improved with semaglutide vs placebo. First&#x02010;hour gastric emptying after the meal was delayed with semaglutide vs placebo (AUC<sub>0&#x02010;1h</sub>; estimated treatment ratio: 0.73 [0.61, 0.87]); this may have contributed to the lower postprandial glucose increase in semaglutide&#x02010;treated subjects. Overall gastric emptying (AUC<sub>0&#x02010;5h</sub>) was not statistically different between treatments. Fasting and postprandial PYY responses were significantly lower with semaglutide vs placebo (<italic>P</italic>&#x02009;=&#x02009;.0397 and <italic>P</italic>&#x02009;=&#x02009;.0097, respectively).</p></sec><sec id="dom13120-sec-0004"><title>Conclusion</title><p>Semaglutide improved fasting and postprandial glucose and lipid metabolism. Overall gastric emptying was similar to that with placebo; however, the observed first&#x02010;hour delay with semaglutide may contribute to a slower entry of glucose into the circulation.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom13120-kwd-0001">GLP&#x02010;1 analogue</kwd><kwd id="dom13120-kwd-0002">glucose metabolism</kwd><kwd id="dom13120-kwd-0003">incretin therapy</kwd><kwd id="dom13120-kwd-0004">insulin analogues</kwd><kwd id="dom13120-kwd-0005">obesity therapy</kwd><kwd id="dom13120-kwd-0006">phase I&#x02010;II study</kwd></kwd-group><funding-group><award-group><funding-source>Novo Nordisk A/S</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="10"/><word-count count="7100"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom13120</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.2.2 mode:remove_FC converted:05.03.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="self-citation" id="dom13120-cit-9001">
<string-name>
<surname>Hjerpsted</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Flint</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Brooks</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Axelsen</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Kvist</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Blundell</surname>
<given-names>J</given-names>
</string-name>. <article-title>Semaglutide improves postprandial glucose and lipid metabolism, and delays first&#x02010;hour gastric emptying in subjects with obesity</article-title>. <source>Diabetes Obes Metab</source>. <year>2018</year>;20:<fpage>610</fpage>&#x02013;<lpage>619</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/dom.13120">https://doi.org/10.1111/dom.13120</ext-link>
<pub-id pub-id-type="pmid">28941314</pub-id></mixed-citation>
</p><fn-group id="dom13120-ntgp-0101"><fn id="dom13120-note-0101"><p>
<bold>Funding information</bold> This study was funded by an unrestricted grant from Novo Nordisk A/S.</p></fn></fn-group></notes></front><body><sec id="dom13120-sec-0005"><label>1</label><title>INTRODUCTION</title><p>Type 2 diabetes (T2D) is a progressive metabolic disease with increasing prevalence.<xref rid="dom13120-bib-0001" ref-type="ref">1</xref> T2D is characterized by chronic hyperglycaemia caused by insulin resistance or reduced insulin secretion.<xref rid="dom13120-bib-0001" ref-type="ref">1</xref>, <xref rid="dom13120-bib-0002" ref-type="ref">2</xref> Despite the availability of several anti&#x02010;diabetic drugs, there remains an unmet need for better therapies because a significant proportion of individuals with T2D do not achieve recommended treatment targets for glycaemic control.<xref rid="dom13120-bib-0003" ref-type="ref">3</xref> Inadequately controlled T2D can result in various complications, including an increased risk of cardiovascular disease.<xref rid="dom13120-bib-0001" ref-type="ref">1</xref> Hyperlipidaemia often co&#x02010;exists with T2D and is a clear risk factor for atherosclerotic cardiovascular disease.<xref rid="dom13120-bib-0004" ref-type="ref">4</xref> Controlling hyper&#x02010;lipidaemia is one of the central recommendations of the American Heart Association to reduce the risk of cardiovascular disease.<xref rid="dom13120-bib-0005" ref-type="ref">5</xref>
</p><p>Glucagon&#x02010;like peptide&#x02010;1 (GLP&#x02010;1) and peptide PYY (PYY) are gut hormones, colocalized in intestinal L cells, that are released in response to nutrient intake.<xref rid="dom13120-bib-0006" ref-type="ref">6</xref>, <xref rid="dom13120-bib-0007" ref-type="ref">7</xref> GLP&#x02010;1 stimulates insulin secretion and inhibits glucagon secretion in a glucose&#x02010;dependent manner.<xref rid="dom13120-bib-0008" ref-type="ref">8</xref> At physiological levels, GLP&#x02010;1 is also associated with an inhibitory effect on gastric emptying and with lowering of body weight, as the result of reduced appetite and decreased energy intake.<xref rid="dom13120-bib-0008" ref-type="ref">8</xref>, <xref rid="dom13120-bib-0009" ref-type="ref">9</xref>, <xref rid="dom13120-bib-0010" ref-type="ref">10</xref>, <xref rid="dom13120-bib-0011" ref-type="ref">11</xref> These properties have led to the development of GLP&#x02010;1 receptor agonists (GLP&#x02010;1RAs) as a treatment option for individuals with T2D, with one GLP&#x02010;1RA also developed for the treatment of obesity.<xref rid="dom13120-bib-0012" ref-type="ref">12</xref>
</p><p>GLP&#x02010;1RAs have been associated with improved beta&#x02010;cell function,<xref rid="dom13120-bib-0013" ref-type="ref">13</xref>, <xref rid="dom13120-bib-0014" ref-type="ref">14</xref> and have been shown to lower postprandial glucose levels and reduce lipid responses.<xref rid="dom13120-bib-0015" ref-type="ref">15</xref>, <xref rid="dom13120-bib-0016" ref-type="ref">16</xref>, <xref rid="dom13120-bib-0017" ref-type="ref">17</xref>, <xref rid="dom13120-bib-0018" ref-type="ref">18</xref> In addition, GLP&#x02010;1RAs have the potential to affect gastric emptying,<xref rid="dom13120-bib-0019" ref-type="ref">19</xref> with an apparently diminished response over time with long&#x02010;acting GLP&#x02010;1RAs.<xref rid="dom13120-bib-0020" ref-type="ref">20</xref>
</p><p>Semaglutide is a human GLP&#x02010;1 analogue currently in development for once&#x02010;weekly treatment of T2D. Semaglutide has 94% structural homology with native human GLP&#x02010;1<xref rid="dom13120-bib-0021" ref-type="ref">21</xref>, <xref rid="dom13120-bib-0022" ref-type="ref">22</xref> with 3 important modifications: an amino acid substitution at position 8 that makes it less susceptible to degradation by dipeptidyl peptidase&#x02010;4; lysine acylation of the peptide backbone, with a spacer and C&#x02010;18 fatty di&#x02010;acid chain at position 26 that provides strong, specific binding to albumin; and another amino acid substitution at position 34, which prevents C&#x02010;18 fatty di&#x02010;acid binding at the wrong site.<xref rid="dom13120-bib-0021" ref-type="ref">21</xref> These modifications give semaglutide an extended half&#x02010;life of approximately 1&#x02009;week,<xref rid="dom13120-bib-0021" ref-type="ref">21</xref> making it suitable for once&#x02010;weekly administration,<xref rid="dom13120-bib-0023" ref-type="ref">23</xref>, <xref rid="dom13120-bib-0024" ref-type="ref">24</xref> which has the potential for improving patient compliance and quality of life,<xref rid="dom13120-bib-0022" ref-type="ref">22</xref> compared with first&#x02010;generation GLP&#x02010;1RAs that require once&#x02010; or twice&#x02010;daily dosing.<xref rid="dom13120-bib-0025" ref-type="ref">25</xref> Semaglutide is associated with dose&#x02010;dependent reductions in glycated haemoglobin (HbA1c) levels and body weight in individuals with diabetes.<xref rid="dom13120-bib-0026" ref-type="ref">26</xref>
</p><p>Previously, we reported that semaglutide, compared with placebo, reduced body weight and <italic>ad libitum</italic> energy intake after 12&#x02009;weeks of treatment.<xref rid="dom13120-bib-0027" ref-type="ref">27</xref> This finding was supported by different aspects of homeostatic and hedonic appetite parameters.<xref rid="dom13120-bib-0027" ref-type="ref">27</xref> Here, we report data from the same study on the effects of semaglutide, compared with placebo, on fasting and postprandial glucose and lipid responses, as well as its effects on gastric emptying.</p></sec><sec id="dom13120-sec-0006"><label>2</label><title>MATERIALS AND METHODS</title><sec id="dom13120-sec-0007"><label>2.1</label><title>Study design</title><p>Details of the study design have been described elsewhere.<xref rid="dom13120-bib-0027" ref-type="ref">27</xref> Briefly, this was a single&#x02010;centre, randomized, double&#x02010;blind, 2&#x02010;period, placebo&#x02010;controlled, crossover study (NCT02079870, EudraCT no. 2013&#x02010;000012&#x02010;24). It was conducted in compliance with the International Conference on Harmonisation Good Clinical Practice guidelines<xref rid="dom13120-bib-0028" ref-type="ref">28</xref> and the Declaration of Helsinki.<xref rid="dom13120-bib-0029" ref-type="ref">29</xref>
</p><p>Subjects were randomized 1:1 to 1 of 2 treatment sequences, semaglutide&#x02013;placebo or placebo&#x02013;semaglutide, and received either semaglutide or volume&#x02010;matched placebo, administered subcutaneously once&#x02010;weekly. The starting dose was 0.25&#x02009;mg (4&#x02009;weeks), escalating to 0.5&#x02009;mg (4&#x02009;weeks) and thereafter to 1.0&#x02009;mg (4&#x02009;weeks). Subjects received a 5th dose of 1.0&#x02009;mg at the last visit (an in&#x02010;house stay) of each treatment period, when assessments were conducted. The 2 treatment periods were separated by a washout period of 5 to 7&#x02009;weeks, to allow for elimination of semaglutide before starting the second treatment period.</p></sec><sec id="dom13120-sec-0008"><label>2.2</label><title>Trial population</title><p>Eligible subjects were 18&#x02009;years of age or older, with obesity, defined as a body mass index (BMI) of 30 to 45&#x02009;kg/m<sup>2</sup>, HbA1c &#x0003c;6.5% and a stable body weight (&#x0003c;3&#x02009;kg change during the 3&#x02009;months prior to screening). Key exclusion criteria included: diagnosis of type 1 or type 2 diabetes; anticipated change in lifestyle (eg, eating, exercise or sleeping pattern, including excessive participation in strenuous exercise, as judged by the investigator) during the trial period; history of chronic or idiopathic acute pancreatitis; personal/family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2; previous surgical treatment for obesity; or use of any medication that could interfere with the trial results. Written informed consent was obtained from all participants before any study&#x02010;related activities commenced.</p></sec><sec id="dom13120-sec-0009"><label>2.3</label><title>Assessments and endpoints</title><p>At the end of each 12&#x02010;week treatment period, on Day 1 of the in&#x02010;house stay, subjects were standardized with regard to meals, physical activity and sleep. The last dose of trial drug was administered in the evening. On Day 2, a standardized carbohydrate&#x02010;rich breakfast was served at ~8:00 <sc>am</sc> and assessments were performed over a 5&#x02010;hour postprandial period. The total energy content of the standardized breakfast was 600&#x02009;kcal (2.51&#x02009;MJ, approximate macronutrient composition: energy percentage [E%] 55% carbohydrate, 30 E% fat and 15 E% protein). The breakfast included yoghurt that contained 1500&#x02009;mg paracetamol (Zentiva, Surrey, UK) to allow measurement of gastric emptying.<xref rid="dom13120-bib-0030" ref-type="ref">30</xref> Before (fasting) and up to 5&#x02009;hours after (postprandial) the start of the breakfast, blood was sampled for measurement of glucose, insulin, C&#x02010;peptide, glucagon, paracetamol and PYY<sub>3&#x02013;36</sub> (referred to as PYY). Gastric emptying was assessed by calculating the endpoints derived from paracetamol concentration profiles. Additionally, endpoints were derived from first&#x02010;hour glucose, insulin, C&#x02010;peptide, glucagon, paracetamol and PYY concentration profiles.</p><p>On Day 4, a standardized fat&#x02010;rich breakfast was served at ~8:00 <sc>am</sc> and an 8&#x02010;hour standardized fat&#x02010;rich meal test was performed. The standardized fat&#x02010;rich breakfast had a total energy content of 1000&#x02009;kcal (4.18&#x02009;MJ, approximate macronutrient composition: 66 E% fat, 19 E% carbohydrate and 15 E% protein). Before (fasting) and up to 8&#x02009;hours after (postprandial) the start of the breakfast, blood was sampled for measurement of parameters of lipid and glucose metabolism. Low&#x02010;density lipoprotein (LDL), high&#x02010;density lipoprotein (HDL) and total cholesterol were assessed in the fasted state only, while glucose, insulin, C&#x02010;peptide, glucagon, triglyceride (TG), free fatty acid (FFA), very&#x02010;low&#x02010;density&#x02010;lipoprotein (VLDL) cholesterol and apo&#x02010;lipoprotein B48 (ApoB&#x02010;48) were assessed both in the fasted state and postprandially.</p></sec><sec id="dom13120-sec-0010"><label>2.4</label><title>Analytical and statistical methods</title><p>Blood samples were taken from subjects by venepuncture or cannulation, and serum and plasma were prepared using standard procedures. Plasma concentrations of glucagon and PYY were measured using validated competitive radioimmunoassays (RIAs; GL&#x02010;32K glucagon RIA and PYY&#x02010;67HK human PYY<sub>3&#x02013;36</sub>&#x02010;specific RIA) (both Millipore, UK). Paracetamol was measured in plasma by liquid chromatography&#x02013;tandem mass spectrometry (LC&#x02010;MS/MS). The following parameters were measured in serum using standard validated methods: ApoB&#x02010;48 (ApoB&#x02010;48 Human ELISA; Biovendor Research and Diagnostic Products, UK), glucose, insulin and C&#x02010;peptide (ADVIA Centaur CP Immunoassay System; Siemens Healthineers, UK), FFA (IL ILab 650 Chemistry Analyser; Diamond Diagnostics, UK), HDL, LDL, total cholesterol, TG and VLDL by ELISA (automated methods: Pacific Biomarkers Inc., USA; for further details see: <ext-link ext-link-type="uri" xlink:href="https://pacbio.com">https://pacbio.com</ext-link>).</p><p>Fasting values and paracetamol endpoints were analyzed using a linear mixed model on log&#x02010;transformed data, including treatment and treatment period as fixed effects and subject as random effect. Incremental area under the concentration&#x02013;time curves (iAUC) of glycaemic and lipid parameters were analyzed using a linear mixed model, including treatment and treatment period as fixed effects, fasting value as covariate and subject as random effect.</p><p>Four subjects did not complete the standardized carbohydrate&#x02010;rich breakfast during the second treatment period (17%&#x02013;40% of meals not eaten) and were excluded from the statistical analyses of endpoints related to this meal test, with the exception of the data points relating to gastric emptying, as all subjects consumed the paracetamol&#x02010;containing yoghurt. Two subjects did not complete the standardized fat&#x02010;rich breakfast and were excluded from the statistical analyses of endpoints relating to this meal test. A sensitivity analysis of gastric emptying was done for the 4 subjects who did not complete the standardized breakfast but who consumed the paracetamol&#x02010;containing yoghurt, as well as for 1 subject who, on one occasion, received placebo rather than semaglutide, and 1 subject who had a measurable plasma paracetamol concentration at baseline. Furthermore, sensitivity analyses were performed for glucose and TG endpoints for the 1 subject who received placebo rather than semaglutide on 1 occasion. Findings from the sensitivity analyses supported the overall results.</p><p>The effects of gastric emptying on first&#x02010;hour postprandial glucose absorption were assessed in an exploratory analysis of glucose results, from the same meal as when the paracetamol sampling was performed. Glucose measured before and up to 1&#x02009;hour after the standardized breakfast (AUC<sub>0&#x02010;1h</sub> for glucose) was further analyzed, with or without adjustment for the subject&#x02010;mean&#x02010;centred log&#x02010;transformed AUC<sub>0&#x02010;1h</sub> for paracetamol concentration as covariate.</p></sec></sec><sec id="dom13120-sec-0011"><label>3</label><title>RESULTS</title><sec id="dom13120-sec-0012"><label>3.1</label><title>Subject characteristics</title><p>A total of 30 subjects were randomized to once&#x02010;weekly semaglutide or placebo. At baseline, mean (standard deviation) age, body weight, height and BMI were 42 (11) years, 101.3 (10.5) kg, 1.73 (0.08) m and 33.8 (2.5) kg/m<sup>2</sup>, respectively. Two&#x02010;thirds of the study subjects were male and 90% were Caucasian. Two subjects withdrew because of gastrointestinal adverse events during the first treatment period while receiving semaglutide, resulting in 28 subjects who completed both treatment periods.</p></sec><sec id="dom13120-sec-0013"><label>3.2</label><title>Glucose metabolism</title><sec id="dom13120-sec-0014"><label>3.2.1</label><title>Glucose</title><p>At the end of the 12&#x02010;week treatment period, subjects receiving semaglutide had lower mean fasting concentrations of glucose, compared with those receiving placebo (estimated treatment ratio [ETR]: 0.95 [95% confidence interval (CI): 0.91, 0.98]; <italic>P</italic>&#x02009;=&#x02009;.0079), prior to the standardized carbohydrate&#x02010;rich breakfast (Table <xref rid="dom13120-tbl-0001" ref-type="table-wrap">1</xref>). Following the standardized carbohydrate&#x02010;rich breakfast, postprandial increments (iAUC<sub>0&#x02010;5h</sub>) for glucose were 38.5% lower with semaglutide compared with placebo (estimated treatment difference [ETD]: &#x02212;1.34&#x02009;mmol&#x02009;h/L [95% CI: &#x02212;2.42, &#x02212;0.27]; <italic>P</italic>&#x02009;=&#x02009;.0163) (Figure <xref rid="dom13120-fig-0001" ref-type="fig">1</xref>, Table <xref rid="dom13120-tbl-0001" ref-type="table-wrap">1</xref>). Before the fat&#x02010;rich breakfast, fasting concentrations of glucose were significantly lower for subjects treated with semaglutide vs placebo (ETR: 0.95 [95% CI: 0.92, 0.98]; <italic>P</italic> .0036) (Table <xref rid="dom13120-tbl-0001" ref-type="table-wrap">1</xref>). Following the standardized fat&#x02010;rich breakfast, postprandial values (iAUC<sub>0&#x02010;8h</sub>) of glucose were 32.0% lower with semaglutide compared with placebo (ETD: &#x02212;1.41&#x02009;mmol&#x02009;h/L; <italic>P</italic>&#x02009;=&#x02009;.0087) (Figure <xref rid="dom13120-supitem-0001" ref-type="supplementary-material">S1</xref>, Table <xref rid="dom13120-tbl-0001" ref-type="table-wrap">1</xref>).</p><table-wrap id="dom13120-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Glucose metabolism parameters and PYY after 12&#x02009;weeks of treatment with semaglutide vs placebo</p></caption><table frame="above" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" align="left" valign="bottom" colspan="1"/><th colspan="5" align="left" valign="bottom" rowspan="1">Fasting values</th><th colspan="6" align="left" valign="bottom" rowspan="1">Postprandial values (iAUC<sub>0&#x02013;5h</sub>) following carbohydrate&#x02010;rich breakfast</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Semaglutide 1.0&#x02009;mg</th><th align="left" valign="bottom" rowspan="1" colspan="1">Placebo</th><th align="left" valign="bottom" rowspan="1" colspan="1">ETR</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">Semaglutide 1.0&#x02009;mg</th><th align="left" valign="bottom" rowspan="1" colspan="1">Placebo</th><th align="left" valign="bottom" rowspan="1" colspan="1">ETD</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">Relative difference (%)<xref ref-type="fn" rid="dom13120-note-0003">a</xref>
</th></tr></thead><tbody valign="top"><tr><td colspan="12" align="left" valign="top" rowspan="1">
<bold>Glucose metabolism parameters</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Glucose</td><td align="left" valign="top" rowspan="1" colspan="1">5.34&#x02009;mmol/L</td><td align="left" valign="top" rowspan="1" colspan="1">5.63&#x02009;mmol/L</td><td align="left" valign="top" rowspan="1" colspan="1">0.95</td><td align="left" valign="top" rowspan="1" colspan="1">0.91, 0.98</td><td align="left" valign="top" rowspan="1" colspan="1">.0079</td><td align="left" valign="top" rowspan="1" colspan="1">2.14&#x02009;mmol&#x02009;h/L</td><td align="left" valign="top" rowspan="1" colspan="1">3.49&#x02009;mmol&#x02009;h/L</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.34&#x02009;mmol&#x02009;h/L</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.42, &#x02212;0.27</td><td align="left" valign="top" rowspan="1" colspan="1">.0163</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;38.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Insulin</td><td align="left" valign="top" rowspan="1" colspan="1">166&#x02009;pmol/L</td><td align="left" valign="top" rowspan="1" colspan="1">115&#x02009;pmol/L</td><td align="left" valign="top" rowspan="1" colspan="1">1.45</td><td align="left" valign="top" rowspan="1" colspan="1">1.20, 1.75</td><td align="left" valign="top" rowspan="1" colspan="1">.0005</td><td align="left" valign="top" rowspan="1" colspan="1">1203&#x02009;pmol&#x02009;h/L</td><td align="left" valign="top" rowspan="1" colspan="1">2124&#x02009;pmol&#x02009;h/L</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;921&#x02009;pmol&#x02009;h/L</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1461,&#x02212;381</td><td align="left" valign="top" rowspan="1" colspan="1">.0018</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;43.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Glucagon</td><td align="left" valign="top" rowspan="1" colspan="1">89.39&#x02009;pg/mL</td><td align="left" valign="top" rowspan="1" colspan="1">104.22&#x02009;pg/mL</td><td align="left" valign="top" rowspan="1" colspan="1">0.86</td><td align="left" valign="top" rowspan="1" colspan="1">0.75, 0.98</td><td align="left" valign="top" rowspan="1" colspan="1">.0224</td><td align="left" valign="top" rowspan="1" colspan="1">31.29&#x02009;pg&#x02009;h/mL</td><td align="left" valign="top" rowspan="1" colspan="1">32.94&#x02009;pg&#x02009;h/mL</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.65&#x02009;pg&#x02009;h/mL</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;24.16, 20.85</td><td align="left" valign="top" rowspan="1" colspan="1">.8811</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;5.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">C&#x02010;peptide</td><td align="left" valign="top" rowspan="1" colspan="1">0.886&#x02009;nmol/L</td><td align="left" valign="top" rowspan="1" colspan="1">0.656&#x02009;nmol/L</td><td align="left" valign="top" rowspan="1" colspan="1">1.35</td><td align="left" valign="top" rowspan="1" colspan="1">1.20, 1.52</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;.0001</td><td align="left" valign="top" rowspan="1" colspan="1">3.541&#x02009;nmol&#x02009;h/L</td><td align="left" valign="top" rowspan="1" colspan="1">4.963&#x02009;nmol&#x02009;h/L</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.42&#x02009;nmol&#x02009;h/L</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.33, &#x02212;0.51</td><td align="left" valign="top" rowspan="1" colspan="1">.0033</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;28.7</td></tr><tr><td colspan="12" align="left" valign="top" rowspan="1">
<bold>PYY</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PYY</td><td align="left" valign="top" rowspan="1" colspan="1">33.89&#x02009;pg/mL</td><td align="left" valign="top" rowspan="1" colspan="1">47.11&#x02009;pg/mL</td><td align="left" valign="top" rowspan="1" colspan="1">0.72</td><td align="left" valign="top" rowspan="1" colspan="1">0.53; 0.98</td><td align="left" valign="top" rowspan="1" colspan="1">.0397</td><td align="left" valign="top" rowspan="1" colspan="1">53.40&#x02009;pg&#x02009;h/mL</td><td align="left" valign="top" rowspan="1" colspan="1">99.50&#x02009;pg&#x02009;h/mL</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;46.10&#x02009;pg&#x02009;h/mL</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;80.52, &#x02212;11.67</td><td align="left" valign="top" rowspan="1" colspan="1">.0097</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;46.3</td></tr></tbody></table><table frame="above" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" align="left" valign="bottom" colspan="1"/><th colspan="5" align="left" valign="bottom" rowspan="1">Fasting values</th><th colspan="6" align="left" valign="bottom" rowspan="1">Postprandial values (iAUC<sub>0&#x02013;8h</sub>) following fat&#x02010;rich breakfast</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Semaglutide 1.0&#x02009;mg</th><th align="left" valign="bottom" rowspan="1" colspan="1">Placebo</th><th align="left" valign="bottom" rowspan="1" colspan="1">ETR</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">Semaglutide 1.0&#x02009;mg</th><th align="left" valign="bottom" rowspan="1" colspan="1">Placebo</th><th align="left" valign="bottom" rowspan="1" colspan="1">ETD</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">Relative difference (%)<xref ref-type="fn" rid="dom13120-note-0003">a</xref>
</th></tr></thead><tbody><tr><td colspan="12" align="left" rowspan="1">
<bold>Glucose metabolism parameters</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Glucose</td><td align="left" rowspan="1" colspan="1">5.14&#x02009;mmol/L</td><td align="left" rowspan="1" colspan="1">5.40&#x02009;mmol/L</td><td align="left" rowspan="1" colspan="1">0.95</td><td align="left" rowspan="1" colspan="1">0.92, 0.98</td><td align="left" rowspan="1" colspan="1">.0036</td><td align="left" rowspan="1" colspan="1">2.99&#x02009;mmol&#x02009;h/L</td><td align="left" rowspan="1" colspan="1">4.39&#x02009;mmol&#x02009;h/L</td><td align="left" rowspan="1" colspan="1">&#x02212;1.41&#x02009;mmol&#x02009;h/L</td><td align="left" rowspan="1" colspan="1">&#x02212;2.43, &#x02212;0.38</td><td align="left" rowspan="1" colspan="1">.0087</td><td align="left" rowspan="1" colspan="1">&#x02212;32.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Insulin</td><td align="left" rowspan="1" colspan="1">135&#x02009;pmol/L</td><td align="left" rowspan="1" colspan="1">114&#x02009;pmol/L</td><td align="left" rowspan="1" colspan="1">1.18</td><td align="left" rowspan="1" colspan="1">0.99, 1.41</td><td align="left" rowspan="1" colspan="1">.0569</td><td align="left" rowspan="1" colspan="1">1993&#x02009;pmol&#x02009;h/L</td><td align="left" rowspan="1" colspan="1">3098&#x02009;pmol&#x02009;h/L</td><td align="left" rowspan="1" colspan="1">&#x02212;1105&#x02009;pmol&#x02009;h/L</td><td align="left" rowspan="1" colspan="1">&#x02212;1811,&#x02212;398</td><td align="left" rowspan="1" colspan="1">.0028</td><td align="left" rowspan="1" colspan="1">&#x02212;35.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Glucagon</td><td align="left" rowspan="1" colspan="1">84.54&#x02009;pg/mL</td><td align="left" rowspan="1" colspan="1">97.40&#x02009;pg/mL</td><td align="left" rowspan="1" colspan="1">0.87</td><td align="left" rowspan="1" colspan="1">0.74, 1.02</td><td align="left" rowspan="1" colspan="1">.0905</td><td align="left" rowspan="1" colspan="1">165.65&#x02009;pg&#x02009;h/mL</td><td align="left" rowspan="1" colspan="1">227.92&#x02009;pg&#x02009;h/mL</td><td align="left" rowspan="1" colspan="1">&#x02212;62.27&#x02009;pg&#x02009;h/mL</td><td align="left" rowspan="1" colspan="1">&#x02212;126.86, 2.32</td><td align="left" rowspan="1" colspan="1">.0582</td><td align="left" rowspan="1" colspan="1">&#x02212;27.3</td></tr><tr><td align="left" rowspan="1" colspan="1">C&#x02010;peptide</td><td align="left" rowspan="1" colspan="1">0.78&#x02009;nmol/L</td><td align="left" rowspan="1" colspan="1">0.63&#x02009;nmol/L</td><td align="left" rowspan="1" colspan="1">1.23</td><td align="left" rowspan="1" colspan="1">1.09, 1.38</td><td align="left" rowspan="1" colspan="1">.0012</td><td align="left" rowspan="1" colspan="1">5.10&#x02009;nmol&#x02009;h/L</td><td align="left" rowspan="1" colspan="1">7.36&#x02009;nmol&#x02009;h/L</td><td align="left" rowspan="1" colspan="1">&#x02212;2.25&#x02009;nmol&#x02009;h/L</td><td align="left" rowspan="1" colspan="1">&#x02212;3.42, &#x02212;1.08</td><td align="left" rowspan="1" colspan="1">.0005</td><td align="left" rowspan="1" colspan="1">&#x02212;30.6</td></tr></tbody></table><table-wrap-foot><fn id="dom13120-note-0002"><p>Abbreviations: CI, confidence interval; ETD, estimated treatment difference (semaglutide &#x02013; placebo); ETR, estimated treatment ratio (semaglutide/placebo); iAUC<sub>0&#x02013;5h</sub>, incremental area under the 0 to 5&#x02010;hour curve; iAUC<sub>0&#x02010;8h</sub>, incremental area under the 0 to 8&#x02010;hour curve; PYY, peptide YY.</p></fn><fn id="dom13120-note-0003"><label>a</label><p>Estimated treatment difference/estimated mean for placebo&#x02009;&#x000d7;&#x02009;100%.</p></fn></table-wrap-foot></table-wrap><fig fig-type="Figure" xml:lang="en" id="dom13120-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Mean glucose metabolism profiles after standardized, carbohydrate&#x02010;rich breakfast. Error bars represent standard error</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-20-610-g001"/></fig></sec><sec id="dom13120-sec-0015"><label>3.2.2</label><title>Insulin and C&#x02010;peptide</title><p>At the end of the 12&#x02010;week treatment period, subjects receiving semaglutide had significantly higher mean fasting concentrations of insulin and C&#x02010;peptide compared with those receiving placebo (ETR: 1.45 [95% CI: 1.20, 1.75]; <italic>P</italic>&#x02009;=&#x02009;.0005; and ETR: 1.35 [95% CI: 1.20, 1.52]; <italic>P</italic>&#x02009;&#x0003c;&#x02009;.0001, respectively), prior to the standardized carbohydrate&#x02010;rich breakfast (Table <xref rid="dom13120-tbl-0001" ref-type="table-wrap">1</xref>). After the standardized carbohydrate&#x02010;rich breakfast, postprandial increments (iAUC<sub>0&#x02010;5h</sub>) were 43.4% and 28.7% lower for insulin and C&#x02010;peptide, respectively, with semaglutide compared with placebo (ETD: &#x02212;921&#x02009;pmol&#x02009;h/L [95% CI: &#x02212;1461, &#x02212;381]; <italic>P&#x02009;=</italic>&#x02009;.0018; and ETD: &#x02212;1.42&#x02009;nmol&#x02009;h/L [95% CI: &#x02212;2.33, &#x02212;0.51]; <italic>P&#x02009;=</italic>&#x02009;.0033, respectively) (Figure <xref rid="dom13120-supitem-0001" ref-type="supplementary-material">S1</xref>, Table <xref rid="dom13120-tbl-0001" ref-type="table-wrap">1</xref>).</p><p>Before the fat&#x02010;rich breakfast, subjects treated with semaglutide also had higher fasting concentrations of insulin and C&#x02010;peptide, although this was only borderline significant for insulin (ETR: 1.18 [95% CI: 0.99, 1.41]; <italic>P</italic>&#x02009;=&#x02009;.0569; and ETR: 1.23 [95% CI: 1.09, 1.38]; <italic>P</italic>&#x02009;=&#x02009;.0012, respectively, Table <xref rid="dom13120-tbl-0001" ref-type="table-wrap">1</xref>). After the standardized fat&#x02010;rich breakfast, postprandial values (iAUC<sub>0&#x02010;8h</sub>) of insulin and C&#x02010;peptide were 35.7% and 30.6% lower for insulin and C&#x02010;peptide, respectively, with semaglutide compared with placebo (ETD: &#x02212;1105&#x02009;pmol&#x02009;h/L, <italic>P&#x02009;=</italic>&#x02009;.0028; and ETD: &#x02212;2.25&#x02009;nmol&#x02009;h/L, <italic>P&#x02009;=</italic>&#x02009;.0005, respectively) (Figure <xref rid="dom13120-supitem-0001" ref-type="supplementary-material">S1</xref>, Table <xref rid="dom13120-tbl-0001" ref-type="table-wrap">1</xref>).</p></sec><sec id="dom13120-sec-0016"><label>3.2.3</label><title>Glucagon</title><p>At the end of the 12&#x02010;week treatment period, subjects receiving semaglutide had lower mean fasting concentrations of glucagon compared with placebo (ETR: 0.86 [95% CI: 0.75, 0.98]; <italic>P</italic>&#x02009;=&#x02009;.0224) prior to the standardized carbohydrate&#x02010;rich breakfast (Table <xref rid="dom13120-tbl-0001" ref-type="table-wrap">1</xref>). Following the standardized carbohydrate&#x02010;rich breakfast, there was no significant difference in postprandial increments (iAUC<sub>0&#x02010;5h</sub>) for glucagon between semaglutide and placebo (Figure <xref rid="dom13120-fig-0001" ref-type="fig">1</xref>, Table <xref rid="dom13120-tbl-0001" ref-type="table-wrap">1</xref>).</p><p>Before and following the standardized fat&#x02010;rich breakfast, fasting and postprandial values (iAUC<sub>0&#x02010;8h</sub>) for glucagon tended to be lower with semaglutide than with placebo (&#x02212;13% and &#x02212;27.3%, respectively) (Figure <xref rid="dom13120-supitem-0001" ref-type="supplementary-material">S1</xref>, Table <xref rid="dom13120-tbl-0001" ref-type="table-wrap">1</xref>).</p></sec></sec><sec id="dom13120-sec-0017"><label>3.3</label><title>Lipid metabolism</title><p>Fasting total cholesterol and HDL cholesterol were lower with semaglutide compared with placebo (ETR: 0.89 [95% CI: 0.86, 0.92]; <italic>P</italic>&#x02009;&#x0003c;&#x02009;.0001; and ETR: 0.92 [95% CI: 0.88, 0.96]; <italic>P</italic>&#x02009;=&#x02009;.0002, respectively), whereas no difference was observed for fasting LDL cholesterol (ETR: 0.95 [95% CI: 0.86, 1.06]; <italic>P</italic>&#x02009;=&#x02009;.3906). Fasting concentrations of TG and VLDL were significantly lower (12% and 21%, respectively) with semaglutide compared with placebo (<italic>P</italic>&#x02009;&#x0003c;&#x02009;.02) (Table <xref rid="dom13120-tbl-0002" ref-type="table-wrap">2</xref>). No difference in FFA and ApoB&#x02010;48 was observed.</p><table-wrap id="dom13120-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Lipid metabolism parameters after 12&#x02009;weeks of treatment with semaglutide vs placebo</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" align="left" valign="bottom" colspan="1">Lipid metabolism parameters</th><th colspan="3" align="left" valign="bottom" rowspan="1">Fasting values</th><th colspan="4" align="left" valign="bottom" rowspan="1">Postprandial values (iAUC<sub>0&#x02013;8h</sub>) following fat&#x02010;rich breakfast</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">ETR</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">ETD</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">Relative difference (%)<xref ref-type="fn" rid="dom13120-note-0005">a</xref>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">TGs</td><td align="left" valign="top" rowspan="1" colspan="1">0.88<xref ref-type="fn" rid="dom13120-note-0006">b</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.80, 0.98</td><td align="left" valign="top" rowspan="1" colspan="1">.0185</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;4.51<xref ref-type="fn" rid="dom13120-note-0006">b</xref> mmol&#x02009;h/L</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;6.15, &#x02212;2.87</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;.0001</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;40.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VLDL</td><td align="left" valign="top" rowspan="1" colspan="1">0.79<xref ref-type="fn" rid="dom13120-note-0006">b</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.66, 0.95</td><td align="left" valign="top" rowspan="1" colspan="1">.0132</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.17<xref ref-type="fn" rid="dom13120-note-0006">b</xref> mmol&#x02009;h/L</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.03, &#x02212;0.32</td><td align="left" valign="top" rowspan="1" colspan="1">.0093</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;42.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ApoB&#x02010;48</td><td align="left" valign="top" rowspan="1" colspan="1">1.02</td><td align="left" valign="top" rowspan="1" colspan="1">0.86, 1.21</td><td align="left" valign="top" rowspan="1" colspan="1">.8376</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.046<xref ref-type="fn" rid="dom13120-note-0006">b</xref> g&#x02009;h/L</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.069, &#x02212;0.022</td><td align="left" valign="top" rowspan="1" colspan="1">.0003</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;49.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FFA</td><td align="left" valign="top" rowspan="1" colspan="1">0.99</td><td align="left" valign="top" rowspan="1" colspan="1">0.88, 1.11</td><td align="left" valign="top" rowspan="1" colspan="1">.8008</td><td align="left" valign="top" rowspan="1" colspan="1">0.052&#x02009;mmol&#x02009;h/L</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.060, 0.163</td><td align="left" valign="top" rowspan="1" colspan="1">.3480</td><td align="left" valign="top" rowspan="1" colspan="1">15.6</td></tr></tbody></table><table-wrap-foot><fn id="dom13120-note-0004"><p>Abbreviations: ApoB&#x02010;48, apolipoprotein B48; CI, confidence interval; ETD, estimated treatment difference (semaglutide &#x02013; placebo); ETR, estimated treatment ratio (semaglutide/placebo); FFA, free fatty acids; iAUC<sub>0&#x02013;8h</sub>, incremental area under the 0 to 8&#x02010;hour curve; TG, triglyceride; VLDL, very&#x02010;low&#x02010;density lipoprotein.</p></fn><fn id="dom13120-note-0005"><label>a</label><p>Estimated treatment difference/estimated mean for placebo &#x000d7; 100%.</p></fn><fn id="dom13120-note-0006"><label>b</label><p>
<italic>P</italic>&#x02009;&#x0003c;&#x02009;.05.</p></fn></table-wrap-foot></table-wrap><p>Following the fat&#x02010;rich breakfast, postprandial values (iAUC<sub>0&#x02010;8h</sub>) were significantly lower for TG (&#x02212;40.7%), VLDL (&#x02212;42.8%) and ApoB&#x02010;48 (&#x02212;49.6%) with semaglutide compared with placebo (ETD: &#x02212;4.51&#x02009;mmol&#x02009;h/L, &#x02212;1.17&#x02009;mmol&#x02009;h/L and &#x02212;0.046&#x02009;g h/L, respectively; <italic>P</italic>&#x02009;&#x0003c;&#x02009;.01 for all) (Figure <xref rid="dom13120-fig-0002" ref-type="fig">2</xref>; Table <xref rid="dom13120-tbl-0002" ref-type="table-wrap">2</xref>). No difference in FFA was observed.</p><fig fig-type="Figure" xml:lang="en" id="dom13120-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Mean lipid metabolism profiles after standardized, fat&#x02010;rich breakfast. Error bars represent standard error. Abbreviation: VLDL, very&#x02010;low&#x02010;density lipoprotein</p></caption><graphic id="nlm-graphic-3" xlink:href="DOM-20-610-g002"/></fig></sec><sec id="dom13120-sec-0018"><label>3.4</label><title>Gastric emptying</title><p>As assessed by paracetamol concentrations, gastric emptying during the first hour, following the standardized carbohydrate&#x02010;rich breakfast, was 27% lower with semaglutide, compared with placebo (AUC<sub>0&#x02013;1h</sub> ETR: 0.73 [95% CI: 0.61, 0.87]; <italic>P</italic>&#x02009;=&#x02009;.0012). There was no significant difference between treatments for the overall postprandial gastric emptying (AUC<sub>0&#x02013;5h</sub> ETR: 0.94 [95% CI: 0.88; 1.01]) (Figure <xref rid="dom13120-fig-0003" ref-type="fig">3</xref>A).</p><fig fig-type="Figure" xml:lang="en" id="dom13120-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Gastric emptying: A, mean paracetamol profiles following standardized, carbohydrate&#x02010;rich breakfast. B, Mean PYY profile following standardized, carbohydrate&#x02010;rich breakfast. Error bars represent standard error. Abbreviation: PYY, peptide YY</p></caption><graphic id="nlm-graphic-5" xlink:href="DOM-20-610-g003"/></fig></sec><sec id="dom13120-sec-0019"><label>3.5</label><title>Effect of gastric emptying on glucose response</title><p>Following the standardized carbohydrate&#x02010;rich breakfast, the postprandial increment for glucose within the first hour (iAUC<sub>0&#x02010;1h</sub>) was 37.8% lower with semaglutide than with placebo (ETD: &#x02212;0.56&#x02009;mmol h/L [95% CI: &#x02212;0.88, &#x02212;0.23]; <italic>P</italic>&#x02009;=&#x02009;.0018). When gastric emptying during the first hour after the meal was included as a covariate, treatment difference was less pronounced (ETD: &#x02212;0.33&#x02009;mmol h/L [95% CI: &#x02212;0.70, 0.05]; <italic>P</italic>&#x02009;=&#x02009;.0829), indicating that approximately 40% of the early glucose response may be explained by the rate of gastric emptying.</p></sec><sec id="dom13120-sec-0020"><label>3.6</label><title>PYY response</title><p>At the end of the 12&#x02010;week treatment period, subjects receiving semaglutide 1.0&#x02009;mg had lower mean fasting PYY concentrations, compared with those receiving placebo (ETR: 0.72 [95% CI: 0.53; 0.98]; <italic>P</italic>&#x02009;=&#x02009;.0397). Postprandial values (iAUC<sub>0&#x02013;5h</sub>) for PYY concentrations, following the standardized carbohydrate&#x02010;rich breakfast, were 46.3% lower with semaglutide, compared with placebo (ETD: &#x02212;46.10&#x02009;pg h/mL; <italic>P</italic>&#x02009;=&#x02009;.0097) (Figure <xref rid="dom13120-fig-0003" ref-type="fig">3</xref>B).</p></sec></sec><sec id="dom13120-sec-0021"><label>4</label><title>DISCUSSION</title><p>In this study we report that fasting and postprandial glucose and lipid metabolism were improved with semaglutide treatment compared with placebo.</p><p>Postprandial glucose and lipid metabolism are important aspects when considering overall glycaemic and lipid control because most individuals spend a significant amount of the day in a non&#x02010;fasting state.<xref rid="dom13120-bib-0019" ref-type="ref">19</xref>, <xref rid="dom13120-bib-0031" ref-type="ref">31</xref>
</p><p>Following 12&#x02009;weeks of treatment with semaglutide, there were generally lower postprandial increments of glucose&#x02010;related parameters, including glucose, glucagon, insulin and C&#x02010;peptide. However, the differences in glucose parameters were less pronounced between treatments following the fat&#x02010;rich breakfast, possibly as a result of the expected reduction in glucose absorption associated with a high fat intake,<xref rid="dom13120-bib-0032" ref-type="ref">32</xref> and/or the lower absolute amount of carbohydrate in the fat&#x02010;rich breakfast vs the carbohydrate&#x02010;rich breakfast (50&#x02009;g vs 83&#x02009;g).<xref rid="dom13120-bib-0033" ref-type="ref">33</xref>
</p><p>Our findings in a population with obesity, but not T2D, are in alignment with results from previous studies with GLP&#x02010;1RAs.<xref rid="dom13120-bib-0015" ref-type="ref">15</xref>, <xref rid="dom13120-bib-0016" ref-type="ref">16</xref>, <xref rid="dom13120-bib-0017" ref-type="ref">17</xref>, <xref rid="dom13120-bib-0034" ref-type="ref">34</xref>, <xref rid="dom13120-bib-0035" ref-type="ref">35</xref> Liraglutide has been shown to significantly reduce mean postprandial glucose and glucagon (AUC<sub>0&#x02010;5h</sub>) compared with placebo, both in subjects with T2D,<xref rid="dom13120-bib-0015" ref-type="ref">15</xref> and in obese, non&#x02010;diabetic adults.<xref rid="dom13120-bib-0035" ref-type="ref">35</xref> Similarly, albiglutide and dulaglutide, both of which are once&#x02010;weekly GLP&#x02010;1RAs, have been shown to lower fasting and postprandial glucose concentrations.<xref rid="dom13120-bib-0017" ref-type="ref">17</xref>, <xref rid="dom13120-bib-0034" ref-type="ref">34</xref> In relation to glycaemic control, GLP&#x02010;1RAs increase insulin secretion in a glucose&#x02010;dependent manner, suppress glucagon and slow gastric emptying, which affects the postprandial glucose response.<xref rid="dom13120-bib-0013" ref-type="ref">13</xref>, <xref rid="dom13120-bib-0014" ref-type="ref">14</xref>, <xref rid="dom13120-bib-0019" ref-type="ref">19</xref> The observed reduction in postprandial insulin and C&#x02010;peptide in this trial may be explained, in part, by the reduction in glucose concentrations observed after 12&#x02009;weeks of treatment. It is conceivable that semaglutide may produce a greater response in subjects with T2D with higher glycaemia.<xref rid="dom13120-bib-0015" ref-type="ref">15</xref>, <xref rid="dom13120-bib-0035" ref-type="ref">35</xref>, <xref rid="dom13120-bib-0036" ref-type="ref">36</xref> In another 12&#x02010;week study with semaglutide in subjects with T2D, a pronounced improvement of beta&#x02010;cell function was shown, and the impact on 24&#x02010;hour glucose, insulin and C&#x02010;peptide responses during a test day with 3 standardized meals was similar to observations in the current study.<xref rid="dom13120-bib-0036" ref-type="ref">36</xref> The effects of semaglutide on insulin and glucose are interdependent. In the fasting state, the concentrations of insulin and C&#x02010;peptide are significantly increased. However, after 12 weeks of treatment, in the postprandial state the lower insulin increments should be interpreted in light of the concurrent lower glucose increments.</p><p>Previously we reported an observed body weight reduction of 5.0&#x02009;kg following 12&#x02009;weeks of semaglutide treatment.<xref rid="dom13120-bib-0027" ref-type="ref">27</xref> Body weight loss is known to improve insulin sensitivity.<xref rid="dom13120-bib-0037" ref-type="ref">37</xref> Improved insulin sensitivity would result in a decrease in glucose concentrations and, thus, less insulin demand. Therefore, weight loss reported in this study may have affected the glucose and lipid responses. Similar findings have been reported with liraglutide, which improved both postprandial glycaemia and induced weight loss.<xref rid="dom13120-bib-0035" ref-type="ref">35</xref> The substantial reduction in body weight reported in this study may, therefore, be the effect of an indirect route by which semaglutide influences postprandial glycaemic and lipid parameters. The long&#x02010;term effects of continuous subcutaneous infusion of GLP&#x02010;1 also showed decreases in both fasting and postprandial glucose concentrations, as well as decreases in HbA1c and body weight.<xref rid="dom13120-bib-0038" ref-type="ref">38</xref>
</p><p>Our study is the first to investigate the effect of semaglutide treatment on postprandial lipid absorption and metabolism. Following a standardized fat&#x02010;rich breakfast, subjects treated with semaglutide had lower postprandial TG, VLDL and ApoB&#x02010;48 over 8&#x02009;hours (iAUC<sub>0&#x02013;8h</sub>). Postprandial ApoB&#x02010;48, a marker of TG uptake from the gut, is known to be involved in the assembly of chylomicron particles required for the absorption of TGs.<xref rid="dom13120-bib-0039" ref-type="ref">39</xref> Chylomicron production has been shown to be increased in subjects with T2D and insulin resistance.<xref rid="dom13120-bib-0039" ref-type="ref">39</xref> In this study the lower postprandial TG concentrations corresponded well with lower postprandial ApoB&#x02010;48 concentration profiles for semaglutide vs placebo. It is plausible that, by reducing the serum concentration of ApoB&#x02010;48, semaglutide in turn reduces the postprandial absorption of serum TGs. In a series of studies in hamsters and mice, Hsieh and colleagues showed that the GLP&#x02010;1 receptor is essential for regulation of the intestinal lipid and lipoprotein metabolism, through control of intestinal lipoprotein synthesis and secretion.<xref rid="dom13120-bib-0040" ref-type="ref">40</xref> This was confirmed in humans by Verg&#x000e8;s and colleagues, who recently reported on the effects of liraglutide on the metabolism of ApoB&#x02010;48.<xref rid="dom13120-bib-0041" ref-type="ref">41</xref> Treatment with liraglutide significantly decreased postprandial hyperlipidaemia in subjects with T2D via a mechanism of reduced ApoB&#x02010;48 production and increased ApoB&#x02010;48 catabolism.<xref rid="dom13120-bib-0041" ref-type="ref">41</xref>
</p><p>The frequency of obesity is reported to be greater in consumers of high&#x02010;fat diets than in consumers of low&#x02010;fat diets.<xref rid="dom13120-bib-0042" ref-type="ref">42</xref> Therefore, the demonstrable effect of semaglutide on blood lipids during a high&#x02010;fat meal is highly relevant for subjects with obesity, who often consume energy&#x02010;dense, high&#x02010;fat foods that contribute to hyperlipidaemia.</p><p>In our study, fasting concentrations of TG and VLDL were also significantly lower with semaglutide than with placebo. In addition, total cholesterol and HDL cholesterol were lower with semaglutide than with placebo, whereas LDL cholesterol appeared to be comparable between treatments. In longer&#x02010;term studies with semaglutide, 1 to 2&#x02009;years of treatment modestly improved various lipid parameters in subjects with T2D compared with placebo or treatment with sitagliptin.<xref rid="dom13120-bib-0043" ref-type="ref">43</xref>, <xref rid="dom13120-bib-0044" ref-type="ref">44</xref> These findings are consistent with those for other GLP&#x02010;1RAs, including liraglutide and exenatide.<xref rid="dom13120-bib-0018" ref-type="ref">18</xref>, <xref rid="dom13120-bib-0045" ref-type="ref">45</xref>, <xref rid="dom13120-bib-0046" ref-type="ref">46</xref>
</p><p>Hyperlipidaemia is a well&#x02010;known risk factor for cardiovascular diseases.<xref rid="dom13120-bib-0047" ref-type="ref">47</xref>, <xref rid="dom13120-bib-0048" ref-type="ref">48</xref> Thus, lowering serum TGs may reduce the risk of cardiovascular diseases such as atherosclerosis.<xref rid="dom13120-bib-0005" ref-type="ref">5</xref> In particular, lowering of non&#x02010;fasting TG could be of clinical importance as higher concentrations have been shown to be associated with an increased risk of myocardial infarction, ischaemic heart disease and death.<xref rid="dom13120-bib-0048" ref-type="ref">48</xref> The effect of semaglutide on cardiovascular outcomes in subjects with T2D has been reported in the 2&#x02010;year SUSTAIN 6 study.<xref rid="dom13120-bib-0044" ref-type="ref">44</xref> Results from this study showed that, among subjects with T2D at high cardiovascular risk, the rate of first occurrence of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke was significantly lower in those receiving semaglutide than in those receiving placebo.<xref rid="dom13120-bib-0044" ref-type="ref">44</xref> The effect of semaglutide on postprandial glucose and lipid metabolism may have contributed to these findings.</p><p>GLP&#x02010;1RAs have the capacity to slow gastric emptying in a variable but marked manner, when administered acutely, which may represent a key mechanism contributing to their glucose&#x02010;lowering effect.<xref rid="dom13120-bib-0019" ref-type="ref">19</xref> However, some investigations indicate that this phenomenon is transient and the effect on gastric emptying diminishes over time.<xref rid="dom13120-bib-0049" ref-type="ref">49</xref>, <xref rid="dom13120-bib-0050" ref-type="ref">50</xref> The differing durations of action of GLP&#x02010;1RAs seem to influence gastric emptying with continued dosing. The slowing of gastric emptying induced by several long&#x02010;acting GLP&#x02010;1 agonists<xref rid="dom13120-bib-0049" ref-type="ref">49</xref>, <xref rid="dom13120-bib-0051" ref-type="ref">51</xref> (although not by exenatide twice daily or lixisenatide) lessens with time, perhaps indicative of adaptation over time.<xref rid="dom13120-bib-0019" ref-type="ref">19</xref> In our study, after 12&#x02009;weeks of treatment, there was no statistically significant difference between semaglutide and placebo for the overall rate of postprandial gastric emptying. A delayed gastric emptying response was detected during the first hour after the standardized breakfast compared with placebo. This finding is consistent with previous findings for liraglutide.<xref rid="dom13120-bib-0018" ref-type="ref">18</xref>, <xref rid="dom13120-bib-0019" ref-type="ref">19</xref> Gastric emptying during the first hour was a significant covariate in the statistical analysis of postprandial glucose response following the standardized breakfast, indicating that approximately 40% of the initial glucose response could be explained by the rate of gastric emptying, and that gastric emptying contributed to the lower postprandial increase in glucose response observed when subjects were treated with semaglutide.</p><p>We used the paracetamol absorption test to measure the rate of gastric emptying. Although it provides an indirect estimation of gastric emptying, this technique is reported to correlate generally well with scintigraphy.<xref rid="dom13120-bib-0052" ref-type="ref">52</xref> A limitation with all gastric emptying tests is the considerable inter&#x02010;individual variation;<xref rid="dom13120-bib-0052" ref-type="ref">52</xref> however, this was counteracted by intra&#x02010;subject comparisons in this study. Despite claimed limitations in drawing conclusions about solids from paracetamol studies,<xref rid="dom13120-bib-0052" ref-type="ref">52</xref> it should be noted that paracetamol in this study was added to the semi&#x02010;solid part of the meal (yoghurt). In a previous study investigating the effect of liraglutide on gastric emptying,<xref rid="dom13120-bib-0018" ref-type="ref">18</xref> a comparable set&#x02010;up was used and similar results were observed with the paracetamol test and the octanoate breath test (labelling the solid part of the meal) during the same meal. Furthermore, the results on gastric emptying obtained in the current study agree with observations in other long&#x02010;acting GLP&#x02010;1RA studies.<xref rid="dom13120-bib-0053" ref-type="ref">53</xref>, <xref rid="dom13120-bib-0054" ref-type="ref">54</xref>
</p><p>The lower PYY response observed with semaglutide is in alignment with a previous study in which GLP&#x02010;1 infusions appeared to have an inhibitory effect on PYY release, suggesting possible feedback (suppression) of GLP&#x02010;1 on L&#x02010;cell function in the acute setting.<xref rid="dom13120-bib-0055" ref-type="ref">55</xref> GLP&#x02010;1RAs have also been reported to reduce postprandial endogenous GLP&#x02010;1 and PYY concentrations.<xref rid="dom13120-bib-0056" ref-type="ref">56</xref> As with GLP&#x02010;1, PYY responses correlate with nutrient exposure in the gut. For the standardized breakfast, the amount consumed was the same for those receiving semaglutide and those receiving placebo, but a lower postprandial PYY response was expected with semaglutide treatment, because of the lower initial gastric emptying. The lower fasting level of PYY may further be explained by a semaglutide&#x02010;induced lower food intake during the treatment period, reported from the same study.<xref rid="dom13120-bib-0027" ref-type="ref">27</xref> Therefore, it is not clear if the reduced PYY response in this study is the result of the semaglutide&#x02010;induced direct suppression of L&#x02010;cell secretion, or is an indirect result of lower postprandial stimulation of L&#x02010;cells caused by delayed gastric emptying or by longer&#x02010;term lower food intake because of the documented impact of semaglutide on appetite regulation.<xref rid="dom13120-bib-0027" ref-type="ref">27</xref>
</p><p>The strengths of this study include the crossover design, with subjects serving as their own control, the high degree of standardization, and the frequency of sampling, up to 5 and 8&#x02009;hours after the standardized meals. A potential weakness is that, of those subjects receiving semaglutide, 4 did not ingest all of the standardized breakfast meal (consuming approximately 60%&#x02010;83%) and, likewise, 2 subjects consumed only part of the standardized fat&#x02010;rich breakfast. Therefore, related data derived from these subjects were excluded from the glucose and TG results. Nevertheless, sensitivity analyses confirmed the results from the primary analyses.</p><p>To conclude, fasting and postprandial glucose and lipid metabolism were improved after 12&#x02009;weeks of treatment with semaglutide compared with placebo. Overall, 5&#x02009;hours postprandial gastric emptying was similar for semaglutide and placebo; with semaglutide, however, a delay was observed during the first hour after a meal, possibly contributing to a slower entry of glucose into the circulation.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom13120-supitem-0001"><caption><p>
<bold>Figure S1.</bold> Glucose metabolism after fat&#x02010;rich breakfast. Error bars represent standard error.</p></caption><media xlink:href="DOM-20-610-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom13120-sec-0022"><title>ACKNOWLEDGMENTS</title><p>We thank all the participants, investigators and trial&#x02010;site staff who were involved in the conduct of the trial. We also thank Haydn Liang, PhD, and Ian Seymour, PhD, both from AXON Communications, for medical writing and editorial assistance.</p><sec id="dom13120-sec-0023" sec-type="COI-statement"><title>Conflict of interests</title><p>M. B. A., A. F., J. B. H. and T. K. are full&#x02010;time employees of, and hold shares in, Novo Nordisk A/S. A. B. has received research grants from Novo Nordisk. J. B. has received research, travel and accommodation grants within the submitted work from Novo Nordisk A/S, and advisory and speaker fees outside the submitted work from Novo Nordisk A/S.</p></sec><sec id="dom13120-sec-0024"><title>Author contributions</title><p>J. B., A. F and J. B. H. designed the study. A. B. and J. B. conducted the study. T. K. participated in the data analysis. M. B. A., A. B., J. B., A. F. and J. B. H. participated in the collection, analysis and interpretation of data. All authors were involved in the writing and revision, and gave final approval, of the manuscript.</p></sec></ack><ref-list id="dom13120-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="dom13120-bib-0001"><label>1</label><mixed-citation publication-type="book" id="dom13120-cit-0002">
<collab collab-type="authors">International Diabetes Federation</collab>
. <source>IDF Diabetes Atlas</source>. <edition>7th</edition> ed. IDF Web site. <ext-link ext-link-type="uri" xlink:href="http://www.diabetesatlas.org/component/attachments/?task=download&#x00026;id=116">www.diabetesatlas.org/component/attachments/?task=download&#x00026;id=116</ext-link>. IDF, 2015. Accessed August 16, 2017.</mixed-citation></ref><ref id="dom13120-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom13120-cit-0003">
<collab collab-type="authors">American Diabetes Association</collab>
. <article-title>Classification and diagnosis of diabetes</article-title>. <source>Diabetes Care</source>. <year>2016</year>;<volume>39</volume>:<fpage>S13</fpage>&#x02013;<lpage>S22</lpage>.<pub-id pub-id-type="pmid">26696675</pub-id></mixed-citation></ref><ref id="dom13120-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom13120-cit-0004">
<string-name>
<surname>Raccah</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Chou</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Colagiuri</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin</article-title>. <source>Diabetes Metab Res Rev</source>. <year>2017</year>;<volume>33</volume>: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/dmrr.2858">https://doi.org/10.1002/dmrr.2858</ext-link>. [Epub 13 Oct 2016].</mixed-citation></ref><ref id="dom13120-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom13120-cit-0005">
<collab collab-type="authors">American Diabetes Association</collab>
. <article-title>Cardiovascular disease and risk management</article-title>. <source>Diabetes Care</source>. <year>2017</year>;<volume>40</volume>:<fpage>S75</fpage>&#x02013;<lpage>S87</lpage>.<pub-id pub-id-type="pmid">27979896</pub-id></mixed-citation></ref><ref id="dom13120-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom13120-cit-0006">
<string-name>
<surname>Stone</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Lichtenstein</surname>
<given-names>AH</given-names>
</string-name>, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <article-title>2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</article-title>. <source>Circulation</source>. <year>2014</year>;<volume>129</volume>:<fpage>S1</fpage>&#x02013;<lpage>S45</lpage>.<pub-id pub-id-type="pmid">24222016</pub-id></mixed-citation></ref><ref id="dom13120-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom13120-cit-0007">
<string-name>
<surname>Ronveaux</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Tome</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Raybould</surname>
<given-names>HE</given-names>
</string-name>. <article-title>Glucagon&#x02010;like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling</article-title>. <source>J Nutr</source>. <year>2015</year>;<volume>145</volume>:<fpage>672</fpage>&#x02013;<lpage>680</lpage>.<pub-id pub-id-type="pmid">25833771</pub-id></mixed-citation></ref><ref id="dom13120-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom13120-cit-0008">
<string-name>
<surname>Habib</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Richards</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Rogers</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Reimann</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Gribble</surname>
<given-names>FM</given-names>
</string-name>. <article-title>Co&#x02010;localisation and secretion of glucagon&#x02010;like peptide 1 and peptide YY from primary cultured human L cells</article-title>. <source>Diabetologia</source>. <year>2013</year>;<volume>56</volume>:<fpage>1413</fpage>&#x02013;<lpage>1416</lpage>.<pub-id pub-id-type="pmid">23519462</pub-id></mixed-citation></ref><ref id="dom13120-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom13120-cit-0009">
<string-name>
<surname>Meier</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Gethmann</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>G&#x000f6;tze</surname>
<given-names>O</given-names>
</string-name>, et al. <article-title>Glucagon&#x02010;like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non&#x02010;esterified fatty acids in humans</article-title>. <source>Diabetologia</source>. <year>2006</year>;<volume>49</volume>:<fpage>452</fpage>&#x02013;<lpage>458</lpage>.<pub-id pub-id-type="pmid">16447057</pub-id></mixed-citation></ref><ref id="dom13120-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom13120-cit-0010">
<string-name>
<surname>Flint</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Raben</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Astrup</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Holst</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>Glucagon&#x02010;like peptide 1 promotes satiety and suppresses energy intake in humans</article-title>. <source>J Clin Invest</source>. <year>1998</year>;<volume>101</volume>:<fpage>515</fpage>&#x02013;<lpage>520</lpage>.<pub-id pub-id-type="pmid">9449682</pub-id></mixed-citation></ref><ref id="dom13120-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom13120-cit-0011">
<string-name>
<surname>Flint</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Raben</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ersb&#x000f8;ll</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Holst</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Astrup</surname>
<given-names>A</given-names>
</string-name>. <article-title>The effect of physiological levels of glucagon&#x02010;like peptide&#x02010;1 on appetite, gastric emptying, energy and substrate metabolism in obesity</article-title>. <source>Int J Obes Relat Metab Disord</source>. <year>2001</year>;<volume>25</volume>:<fpage>781</fpage>&#x02013;<lpage>792</lpage>.<pub-id pub-id-type="pmid">11439290</pub-id></mixed-citation></ref><ref id="dom13120-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom13120-cit-0012">
<string-name>
<surname>Wettergren</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schjoldager</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Mortensen</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Myhre</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Christiansen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Holst</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>Truncated GLP&#x02010;1 (proglucagon 78&#x02010;107&#x02010;amide) inhibits gastric and pancreatic functions in man</article-title>. <source>Dig Dis Sci</source>. <year>1993</year>;<volume>38</volume>:<fpage>665</fpage>&#x02013;<lpage>673</lpage>.<pub-id pub-id-type="pmid">8462365</pub-id></mixed-citation></ref><ref id="dom13120-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom13120-cit-0013">
<string-name>
<surname>Pi&#x02010;Sunyer</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Astrup</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fujioka</surname>
<given-names>K</given-names>
</string-name>, et al; SCALE Obesity and Prediabetes NN8022&#x02010;1839 Study Group. <article-title>A randomized, controlled trial of 3.0 mg of liraglutide in weight management</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>373</volume>:<fpage>11</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">26132939</pub-id></mixed-citation></ref><ref id="dom13120-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom13120-cit-0014">
<string-name>
<surname>Hare</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Vilsb&#x000f8;ll</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Asmar</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Deacon</surname>
<given-names>CF</given-names>
</string-name>, <string-name>
<surname>Knop</surname>
<given-names>FK</given-names>
</string-name>, <string-name>
<surname>Holst</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>The glucagonostatic and insulinotropic effects of glucagon&#x02010;like peptide 1 contribute equally to its glucose&#x02010;lowering action</article-title>. <source>Diabetes</source>. <year>2010</year>;<volume>59</volume>:<fpage>1765</fpage>&#x02013;<lpage>1770</lpage>.<pub-id pub-id-type="pmid">20150286</pub-id></mixed-citation></ref><ref id="dom13120-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dom13120-cit-0015">
<string-name>
<surname>Kondo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Satoh</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Osada</surname>
<given-names>UN</given-names>
</string-name>, <string-name>
<surname>Terauchi</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Early liraglutide treatment improves beta&#x02010;cell function in patients with type 2 diabetes: a retrospective cohort study</article-title>. <source>Endocr J</source>. <year>2015</year>;<volume>62</volume>:<fpage>971</fpage>&#x02013;<lpage>980</lpage>.<pub-id pub-id-type="pmid">26249841</pub-id></mixed-citation></ref><ref id="dom13120-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom13120-cit-0016">
<string-name>
<surname>Flint</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kapitza</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hindsberger</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zdravkovic</surname>
<given-names>M</given-names>
</string-name>. <article-title>The once&#x02010;daily human glucagon&#x02010;like peptide&#x02010;1 (GLP&#x02010;1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients</article-title>. <source>Adv Ther</source>. <year>2011</year>;<volume>28</volume>:<fpage>213</fpage>&#x02013;<lpage>226</lpage>.<pub-id pub-id-type="pmid">21340616</pub-id></mixed-citation></ref><ref id="dom13120-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dom13120-cit-0017">
<string-name>
<surname>Linnebjerg</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kothare</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Skrivanek</surname>
<given-names>Z</given-names>
</string-name>, et al. <article-title>Exenatide: effect of injection time on postprandial glucose in patients with type 2 diabetes</article-title>. <source>Diabet Med</source>. <year>2006</year>;<volume>23</volume>:<fpage>240</fpage>&#x02013;<lpage>245</lpage>.<pub-id pub-id-type="pmid">16492205</pub-id></mixed-citation></ref><ref id="dom13120-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="dom13120-cit-0018">
<string-name>
<surname>Matthews</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Stewart</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>De Boever</surname>
<given-names>EH</given-names>
</string-name>, et al; Albiglutide Study Group. <article-title>Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long&#x02010;acting glucagon&#x02010;like peptide&#x02010;1 mimetic, in patients with type 2 diabetes</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2008</year>;<volume>93</volume>:<fpage>4810</fpage>&#x02013;<lpage>4817</lpage>.<pub-id pub-id-type="pmid">18812476</pub-id></mixed-citation></ref><ref id="dom13120-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="dom13120-cit-0019">
<string-name>
<surname>Hermansen</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Baekdal</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>D&#x000fc;ring</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat&#x02010;rich meal in patients with type 2 diabetes: a randomized, double&#x02010;blind, placebo&#x02010;controlled, cross&#x02010;over trial</article-title>. <source>Diabetes Obes Metab</source>. <year>2013</year>;<volume>15</volume>:<fpage>1040</fpage>&#x02013;<lpage>1048</lpage>.<pub-id pub-id-type="pmid">23683069</pub-id></mixed-citation></ref><ref id="dom13120-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="dom13120-cit-0020">
<string-name>
<surname>Marathe</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Rayner</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Horowitz</surname>
<given-names>M</given-names>
</string-name>. <article-title>Relationships between gastric emptying, postprandial glycemia, and incretin hormones</article-title>. <source>Diabetes Care</source>. <year>2013</year>;<volume>36</volume>:<fpage>1396</fpage>&#x02013;<lpage>1405</lpage>.<pub-id pub-id-type="pmid">23613599</pub-id></mixed-citation></ref><ref id="dom13120-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="dom13120-cit-0021">
<string-name>
<surname>Uccellatore</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Genovese</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dicembrini</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Mannucci</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ceriello</surname>
<given-names>A</given-names>
</string-name>. <article-title>Comparison review of short&#x02010;acting and long&#x02010;acting glucagon&#x02010;like peptide&#x02010;1 receptor agonists</article-title>. <source>Diabetes Ther</source>. <year>2015</year>;<volume>6</volume>:<fpage>239</fpage>&#x02013;<lpage>256</lpage>.<pub-id pub-id-type="pmid">26271795</pub-id></mixed-citation></ref><ref id="dom13120-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="dom13120-cit-0022">
<string-name>
<surname>Lau</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bloch</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sch&#x000e4;ffer</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Discovery of the once&#x02010;weekly glucagon&#x02010;like peptide&#x02010;1 (GLP&#x02010;1) analogue semaglutide</article-title>. <source>J Med Chem</source>. <year>2015</year>;<volume>58</volume>:<fpage>7370</fpage>&#x02013;<lpage>7380</lpage>.<pub-id pub-id-type="pmid">26308095</pub-id></mixed-citation></ref><ref id="dom13120-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="dom13120-cit-0023">
<string-name>
<surname>Saini</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Schoenfeld</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kaulback</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Dubinsky</surname>
<given-names>MC</given-names>
</string-name>. <article-title>Effect of medication dosing frequency on adherence in chronic diseases</article-title>. <source>Am J Manag Care</source>. <year>2009</year>;<volume>15</volume>:<fpage>e22</fpage>&#x02013;<lpage>e33</lpage>.<pub-id pub-id-type="pmid">19514806</pub-id></mixed-citation></ref><ref id="dom13120-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="dom13120-cit-0024">
<string-name>
<surname>Kapitza</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Nosek</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hartvig</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Flint</surname>
<given-names>A</given-names>
</string-name>. <article-title>Semaglutide, a once&#x02010;weekly human GLP&#x02010;1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel</article-title>. <source>J Clin Pharmacol</source>. <year>2015</year>;<volume>55</volume>:<fpage>497</fpage>&#x02013;<lpage>504</lpage>.<pub-id pub-id-type="pmid">25475122</pub-id></mixed-citation></ref><ref id="dom13120-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="dom13120-cit-0025">
<string-name>
<surname>Marbury</surname>
<given-names>TC</given-names>
</string-name>, <string-name>
<surname>Flint</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Jacobsen</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Derving Karsbol</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lasseter</surname>
<given-names>K</given-names>
</string-name>. <article-title>Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon&#x02010;like peptide&#x02010;1 analog, in subjects with and without renal impairment</article-title>. <source>Clin Pharmacokinet</source>. <year>2017</year>;56:1381&#x02013;1390.</mixed-citation></ref><ref id="dom13120-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="dom13120-cit-0026">
<string-name>
<surname>Madsbad</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kielgast</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Asmar</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Deacon</surname>
<given-names>CF</given-names>
</string-name>, <string-name>
<surname>Torekov</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Holst</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>An overview of once&#x02010;weekly glucagon&#x02010;like peptide&#x02010;1 receptor agonists&#x02013;available efficacy and safety data and perspectives for the future</article-title>. <source>Diabetes Obes Metab</source>. <year>2011</year>;<volume>13</volume>:<fpage>394</fpage>&#x02013;<lpage>407</lpage>.<pub-id pub-id-type="pmid">21208359</pub-id></mixed-citation></ref><ref id="dom13120-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="dom13120-cit-0027">
<string-name>
<surname>Nauck</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Petrie</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Sesti</surname>
<given-names>G</given-names>
</string-name>, et al; Study 1821 Investigators. <article-title>A phase 2, randomized, dose&#x02010;finding study of the novel once&#x02010;weekly human GLP&#x02010;1 analog, semaglutide, compared with placebo and open&#x02010;label liraglutide in patients with type 2 diabetes</article-title>. <source>Diabetes Care</source>. <year>2016</year>;<volume>39</volume>:<fpage>231</fpage>&#x02013;<lpage>241</lpage>.<pub-id pub-id-type="pmid">26358288</pub-id></mixed-citation></ref><ref id="dom13120-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="dom13120-cit-0028">
<string-name>
<surname>Blundell</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Finlayson</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Axelsen</surname>
<given-names>MB</given-names>
</string-name>, et al. <article-title>Effects of once&#x02010;weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity</article-title>. <source>Diabetes Obes Metab</source>. <year>2017</year>;19:1242&#x02013;1251.</mixed-citation></ref><ref id="dom13120-bib-0028"><label>28</label><mixed-citation publication-type="miscellaneous" id="dom13120-cit-0029">
<collab collab-type="authors">European Agency for the Evaluation of Medicinal Products</collab>
. International Conference on Harmonisation&#x02010;World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Harmonised Tripartite Guideline. Good Clinical Practice, <year>2017</year>
<ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf</ext-link>. Accessed August 16, 2017.</mixed-citation></ref><ref id="dom13120-bib-0029"><label>29</label><mixed-citation publication-type="miscellaneous" id="dom13120-cit-0030">
<collab collab-type="authors">World Medical Association</collab>
. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Last amended with Note of Clarification on Paragraph 29 by the WMA General Assembly, Washington 2002; and Note of Clarification on Paragraph 30 by the WMA General assembly, Tokyo, 2004. <ext-link ext-link-type="uri" xlink:href="http://www.wma.net/en/30publications/10policies/b3">http://www.wma.net/en/30publications/10policies/b3/</ext-link> Accessed August 16, 2017.</mixed-citation></ref><ref id="dom13120-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="dom13120-cit-0031">
<string-name>
<surname>Medhus</surname>
<given-names>AW</given-names>
</string-name>, <string-name>
<surname>Lofthus</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Bredesen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Husebye</surname>
<given-names>E</given-names>
</string-name>. <article-title>Gastric emptying: the validity of the paracetamol absorption test adjusted for individual pharmacokinetics</article-title>. <source>Neurogastroenterol Motil</source>. <year>2001</year>;<volume>13</volume>:<fpage>179</fpage>&#x02013;<lpage>185</lpage>.<pub-id pub-id-type="pmid">11437980</pub-id></mixed-citation></ref><ref id="dom13120-bib-0031"><label>31</label><mixed-citation publication-type="book" id="dom13120-cit-0032">
<string-name>
<surname>Lopez&#x02010;Miranda</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Marin</surname>
<given-names>C</given-names>
</string-name>. <chapter-title>Dietary, physiological, and genetic impacts on postprandial lipid metabolism</chapter-title> In: <person-group person-group-type="editor"><name><surname>Montmayeur</surname><given-names>JP</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>le Coutre</surname><given-names>J</given-names></name></person-group>, eds. <source>Fat Detection: Taste, Texture, and Post Ingestive Effects</source>. <publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>CRC Press</publisher-name>; <year>2009</year>.</mixed-citation></ref><ref id="dom13120-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="dom13120-cit-0033">
<string-name>
<surname>Pi&#x02010;Sunyer</surname>
<given-names>FX</given-names>
</string-name>. <article-title>Glycemic index and disease</article-title>. <source>Am J Clin Nutr</source>. <year>2002</year>;<volume>76</volume>:<fpage>290S</fpage>&#x02013;<lpage>S298</lpage>.<pub-id pub-id-type="pmid">12081854</pub-id></mixed-citation></ref><ref id="dom13120-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="dom13120-cit-0034">
<string-name>
<surname>Pearce</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Noakes</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Keogh</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Clifton</surname>
<given-names>PM</given-names>
</string-name>. <article-title>Effect of carbohydrate distribution on postprandial glucose peaks with the use of continuous glucose monitoring in type 2 diabetes</article-title>. <source>Am J Clin Nutr</source>. <year>2008</year>;<volume>87</volume>:<fpage>638</fpage>&#x02013;<lpage>644</lpage>.<pub-id pub-id-type="pmid">18326602</pub-id></mixed-citation></ref><ref id="dom13120-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="dom13120-cit-0035">
<string-name>
<surname>Umpierrez</surname>
<given-names>GE</given-names>
</string-name>, <string-name>
<surname>Blevins</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Rosenstock</surname>
<given-names>J</given-names>
</string-name>, et al; EGO Study Group. <article-title>The effects of LY2189265, a long&#x02010;acting glucagon&#x02010;like peptide&#x02010;1 analogue, in a randomized, placebo&#x02010;controlled, double&#x02010;blind study of overweight/obese patients with type 2 diabetes: the EGO study</article-title>. <source>Diabetes Obes Metab</source>. <year>2011</year>;<volume>13</volume>:<fpage>418</fpage>&#x02013;<lpage>425</lpage>.<pub-id pub-id-type="pmid">21251180</pub-id></mixed-citation></ref><ref id="dom13120-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="dom13120-cit-0036">
<string-name>
<surname>van Can</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sloth</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Flint</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Blaak</surname>
<given-names>EE</given-names>
</string-name>, <string-name>
<surname>Saris</surname>
<given-names>WH</given-names>
</string-name>. <article-title>Effects of the once&#x02010;daily GLP&#x02010;1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non&#x02010;diabetic adults</article-title>. <source>Int J Obes (Lond)</source>. <year>2014</year>;<volume>38</volume>:<fpage>784</fpage>&#x02013;<lpage>793</lpage>.<pub-id pub-id-type="pmid">23999198</pub-id></mixed-citation></ref><ref id="dom13120-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="dom13120-cit-0037">
<string-name>
<surname>Kapitza</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dahl</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Jacobsen</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Axelsen</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Flint</surname>
<given-names>A</given-names>
</string-name>. <article-title>Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double&#x02010;blind, placebo&#x02010;controlled trial</article-title>. <source>Diabetologia</source>. <year>2017</year>;<volume>60</volume>:<fpage>1390</fpage>&#x02013;<lpage>1399</lpage>.<pub-id pub-id-type="pmid">28526920</pub-id></mixed-citation></ref><ref id="dom13120-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="dom13120-cit-0038">
<string-name>
<surname>Schenk</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Harber</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Shrivastava</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Burant</surname>
<given-names>CF</given-names>
</string-name>, <string-name>
<surname>Horowitz</surname>
<given-names>JF</given-names>
</string-name>. <article-title>Improved insulin sensitivity after weight loss and exercise training is mediated by a reduction in plasma fatty acid mobilization, not enhanced oxidative capacity</article-title>. <source>J Physiol</source>. <year>2009</year>;<volume>587</volume>:<fpage>4949</fpage>&#x02013;<lpage>4961</lpage>.<pub-id pub-id-type="pmid">19723783</pub-id></mixed-citation></ref><ref id="dom13120-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="dom13120-cit-0039">
<string-name>
<surname>Zander</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Madsbad</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Madsen</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Holst</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>Effect of 6&#x02010;week course of glucagon&#x02010;like peptide 1 on glycaemic control, insulin sensitivity, and beta&#x02010;cell function in type 2 diabetes: a parallel&#x02010;group study</article-title>. <source>Lancet</source>. <year>2002</year>;<volume>359</volume>:<fpage>824</fpage>&#x02013;<lpage>830</lpage>.<pub-id pub-id-type="pmid">11897280</pub-id></mixed-citation></ref><ref id="dom13120-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="dom13120-cit-0040">
<string-name>
<surname>Hussain</surname>
<given-names>MM</given-names>
</string-name>. <article-title>Intestinal lipid absorption and lipoprotein formation</article-title>. <source>Curr Opin Lipidol</source>. <year>2014</year>;<volume>25</volume>:<fpage>200</fpage>&#x02013;<lpage>206</lpage>.<pub-id pub-id-type="pmid">24751933</pub-id></mixed-citation></ref><ref id="dom13120-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="dom13120-cit-0041">
<string-name>
<surname>Hsieh</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Longuet</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Baker</surname>
<given-names>CL</given-names>
</string-name>, et al. <article-title>The glucagon&#x02010;like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice</article-title>. <source>Diabetologia</source>. <year>2010</year>;<volume>53</volume>:<fpage>552</fpage>&#x02013;<lpage>561</lpage>.<pub-id pub-id-type="pmid">19957161</pub-id></mixed-citation></ref><ref id="dom13120-bib-0041"><label>41</label><mixed-citation publication-type="miscellaneous" id="dom13120-cit-0042">
<string-name>
<surname>Verg&#x000e8;s</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Duvillard</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Bouillet</surname>
<given-names>B</given-names>
</string-name>, et al. Liraglutide reduces postprandial hyperlipidaemia by increasing apoB48 catabolism and by reducing apoB48 production. Geneva, Switzerland: 52nd EASD Annual Meeting 2016; Abstract #635.</mixed-citation></ref><ref id="dom13120-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="dom13120-cit-0043">
<string-name>
<surname>Blundell</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Lawton</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Cotton</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Macdiarmid</surname>
<given-names>JI</given-names>
</string-name>. <article-title>Control of human appetite: implications for the intake of dietary fat</article-title>. <source>Annu Rev Nutr</source>. <year>1996</year>;<volume>16</volume>:<fpage>285</fpage>&#x02013;<lpage>319</lpage>.<pub-id pub-id-type="pmid">8839929</pub-id></mixed-citation></ref><ref id="dom13120-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="dom13120-cit-0044">
<string-name>
<surname>Ahr&#x000e9;n</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Masmiquel</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Kumar</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Efficacy and safety of once&#x02010;weekly semaglutide versus once&#x02010;daily sitagliptin as an add&#x02010;on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56&#x02010;week, double&#x02010;blind, phase 3a, randomised trial</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2017</year>;<volume>5</volume>:<fpage>341</fpage>&#x02013;<lpage>354</lpage>.<pub-id pub-id-type="pmid">28385659</pub-id></mixed-citation></ref><ref id="dom13120-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="dom13120-cit-0045">
<string-name>
<surname>Marso</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Bain</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Consoli</surname>
<given-names>A</given-names>
</string-name>, et al; SUSTAIN&#x02010;6 Investigators. <article-title>Semaglutide and cardiovascular outcomes in patients with type 2 diabetes</article-title>. <source>N Engl J Med</source>. <year>2016</year>;<volume>375</volume>:<fpage>1834</fpage>&#x02013;<lpage>1844</lpage>.<pub-id pub-id-type="pmid">27633186</pub-id></mixed-citation></ref><ref id="dom13120-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="dom13120-cit-0046">
<string-name>
<surname>Voukali</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kastrinelli</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Stragalinou</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide</article-title>. <source>J Diabetes Res</source>. <year>2014</year>;<volume>2014</volume>:<fpage>304032</fpage>.<pub-id pub-id-type="pmid">25165723</pub-id></mixed-citation></ref><ref id="dom13120-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="dom13120-cit-0047">
<string-name>
<surname>Ariel</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Abbasi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lamendola</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Reaven</surname>
<given-names>GM</given-names>
</string-name>. <article-title>Effect of liraglutide administration and a calorie&#x02010;restricted diet on lipoprotein profile in overweight/obese persons with prediabetes</article-title>. <source>Nutr Metab Cardiovasc Dis</source>. <year>2014</year>;<volume>24</volume>:<fpage>1317</fpage>&#x02013;<lpage>1322</lpage>.<pub-id pub-id-type="pmid">25280957</pub-id></mixed-citation></ref><ref id="dom13120-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="dom13120-cit-0048">
<string-name>
<surname>Langsted</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Freiberg</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Tybjaerg&#x02010;Hansen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schnohr</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>
<given-names>GB</given-names>
</string-name>, <string-name>
<surname>Nordestgaard</surname>
<given-names>BG</given-names>
</string-name>. <article-title>Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow&#x02010;up</article-title>. <source>J Intern Med</source>. <year>2011</year>;<volume>270</volume>:<fpage>65</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">21198993</pub-id></mixed-citation></ref><ref id="dom13120-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="dom13120-cit-0049">
<string-name>
<surname>Nordestgaard</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Langsted</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Freiberg</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>Nonfasting hyperlipidemia and cardiovascular disease</article-title>. <source>Curr Drug Targets</source>. <year>2009</year>;<volume>10</volume>:<fpage>328</fpage>&#x02013;<lpage>335</lpage>.<pub-id pub-id-type="pmid">19355857</pub-id></mixed-citation></ref><ref id="dom13120-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="dom13120-cit-0050">
<string-name>
<surname>Jelsing</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Vrang</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Hansen</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Raun</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tang&#x02010;Christensen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Knudsen</surname>
<given-names>LB</given-names>
</string-name>. <article-title>Liraglutide: short&#x02010;lived effect on gastric emptying &#x02013; long lasting effects on body weight</article-title>. <source>Diabetes Obes Metab</source>. <year>2012</year>;<volume>14</volume>:<fpage>531</fpage>&#x02013;<lpage>538</lpage>.<pub-id pub-id-type="pmid">22226053</pub-id></mixed-citation></ref><ref id="dom13120-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="dom13120-cit-0051">
<string-name>
<surname>Nauck</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Kemmeries</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Holst</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Meier</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>Rapid tachyphylaxis of the glucagon&#x02010;like peptide 1&#x02010;induced deceleration of gastric emptying in humans</article-title>. <source>Diabetes</source>. <year>2011</year>;<volume>60</volume>:<fpage>1561</fpage>&#x02013;<lpage>1565</lpage>.<pub-id pub-id-type="pmid">21430088</pub-id></mixed-citation></ref><ref id="dom13120-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="dom13120-cit-0052">
<string-name>
<surname>Drucker</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Buse</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>K</given-names>
</string-name>, et al; DURATION&#x02010;1 Study Group. <article-title>Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open&#x02010;label, non&#x02010;inferiority study</article-title>. <source>Lancet</source>. <year>2008</year>;<volume>372</volume>:<fpage>1240</fpage>&#x02013;<lpage>1250</lpage>.<pub-id pub-id-type="pmid">18782641</pub-id></mixed-citation></ref><ref id="dom13120-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="dom13120-cit-0053">
<string-name>
<surname>Willems</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Quartero</surname>
<given-names>AO</given-names>
</string-name>, <string-name>
<surname>Numans</surname>
<given-names>ME</given-names>
</string-name>. <article-title>How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study</article-title>. <source>Dig Dis Sci</source>. <year>2001</year>;<volume>46</volume>:<fpage>2256</fpage>&#x02013;<lpage>2262</lpage>.<pub-id pub-id-type="pmid">11680606</pub-id></mixed-citation></ref><ref id="dom13120-bib-0053"><label>53</label><mixed-citation publication-type="miscellaneous" id="dom13120-cit-0054">Trulicity (Dulaglutide) Prescribing Information. Indianapolis, IN: Eli Lilly and Company, <year>2014</year>
<ext-link ext-link-type="uri" xlink:href="http://pi.lilly.com/us/trulicity-uspi.pdf">http://pi.lilly.com/us/trulicity-uspi.pdf</ext-link> Accessed August 16, 2017.</mixed-citation></ref><ref id="dom13120-bib-0054"><label>54</label><mixed-citation publication-type="miscellaneous" id="dom13120-cit-0055">Tanzeuim (Albiglutide) Prescribing Information. Willington, DE: GlaxoSmithKline LLC, <year>2014</year>
<ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125431s000lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125431s000lbl.pdf</ext-link> Accessed August 16, 2017.</mixed-citation></ref><ref id="dom13120-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="dom13120-cit-0056">
<string-name>
<surname>Naslund</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Bogefors</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Skogar</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>GLP&#x02010;1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans</article-title>. <source>Am J Physiol</source>. <year>1999</year>;<volume>277</volume>:<fpage>R910</fpage>&#x02013;<lpage>R916</lpage>.<pub-id pub-id-type="pmid">10484511</pub-id></mixed-citation></ref><ref id="dom13120-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="dom13120-cit-0057">
<string-name>
<surname>Lin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hodge</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>O'Connor&#x02010;Semmes</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Nunez</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>GSK2374697, a long duration glucagon&#x02010;like peptide&#x02010;1 (GLP&#x02010;1) receptor agonist, reduces postprandial circulating endogenous total GLP&#x02010;1 and peptide YY in healthy subjects</article-title>. <source>Diabetes Obes Metab</source>. <year>2015</year>;<volume>17</volume>:<fpage>1007</fpage>&#x02013;<lpage>1010</lpage>.<pub-id pub-id-type="pmid">26179090</pub-id></mixed-citation></ref></ref-list></back></article>